Report Highlights

U.S. Gestational Diabetes Market: Market Overview

The U.S. gestational diabetes market is structured across three primary axes: diagnostics, therapeutics, and digital disease management. Gestational diabetes mellitus (GDM) affects an estimated 6% to 9% of all pregnancies in the United States, translating to over 300,000 new cases annually. Government policy has historically been the dominant force shaping this market, beginning with the Affordable Care Act's mandate under Section 2713 requiring insurers to cover gestational diabetes screening without cost-sharing, which drove widespread adoption of the standard 75-gram oral glucose tolerance test as recommended by the U.S. Preventive Services Task Force (USPSTF).

Private sector innovation has led primarily in the monitoring and digital therapeutics subsegments, with companies such as Dexcom and Abbott outpacing regulatory guidance with next-generation CGM devices. The therapeutic segment remains largely generic-dominated for oral agents, while insulin delivery is contested between Novo Nordisk, Sanofi, and Eli Lilly. The market's structural growth is underpinned by rising GDM prevalence linked to increasing maternal age and obesity rates—two trends the CDC's Division of Diabetes Translation has flagged in its National Diabetes Statistics Report as accelerating without a clear policy reversal mechanism in place through the forecast period.

Policy-Driven Growth in U.S. Gestational Diabetes

Three specific policy mechanisms are generating measurable demand growth in this market. First, the Affordable Care Act's preventive services mandate (Public Law 111-148, Section 2713), enforced by the Department of Labor and HHS, requires all non-grandfathered health plans to cover GDM screening at no cost to the patient, guaranteeing a funded diagnostic touchpoint for every insured pregnant woman. This mandate directly sustains laboratory glucose testing volumes and has created a compliance-driven baseline revenue floor for diagnostic manufacturers including Roche Diagnostics and Becton Dickinson.

Second, the Centers for Medicare and Medicaid Services' Diabetes Prevention Program (DPP) expansion under the Medicare Diabetes Prevention Program (MDPP) benefit—effective since 2018 and expanded in scope through the Consolidated Appropriations Act of 2023—funds structured lifestyle intervention for individuals with prediabetes and postpartum GDM history. Third, the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), administered by the USDA Food and Nutrition Service with a FY2024 appropriation of USD 7.3 billion, covers dietary counseling and nutritional support for GDM-affected women, generating sustained demand for dietitian-led digital health platforms and glucose monitoring supplies among low-income pregnant populations.

Regulatory Barriers and Compliance Costs

Market entry for gestational diabetes diagnostics and devices is governed primarily by the U.S. Food and Drug Administration's Center for Devices and Radiological Health (CDRH). Blood glucose monitors and CGM systems intended for use in pregnant women require 510(k) clearance or De Novo authorization, and critically, most CGM labels explicitly exclude pregnancy as an indicated use—a regulatory gap that creates both a barrier and a compliance liability. Dexcom's G6 and G7 received pregnancy-specific labeling only after dedicated clinical validation studies, a process that took over 24 months and cost an estimated USD 15–20 million per device iteration. Competitors without equivalent resources face a prohibitive pathway to achieving on-label pregnancy clearance.

Pharmaceutical manufacturers face additional barriers through FDA's Office of Pharmaceutical Quality, where insulin products used off-label in GDM must navigate REMS requirements and pregnancy-specific pharmacovigilance obligations. The Office of Inspector General (OIG) has flagged off-label prescribing of metformin in GDM as a compliance risk in Medicaid billing audits, creating hesitancy among prescribers and formulary managers despite emerging clinical evidence supporting its use. State-level Medicaid prior authorization requirements for CGM devices in pregnancy—administered inconsistently across 50 state agencies—add an average 14-day approval delay per patient, suppressing real-world adoption rates below clinically optimal levels and increasing administrative costs for hospital systems managing high-risk obstetric populations.

Policy-Created Opportunities in U.S. Gestational Diabetes

The most immediate policy-created opportunity lies within the CMS Innovation Center's Transforming Maternal Health (TMaH) model, announced in 2023 and targeting Medicaid managed care organizations in up to 15 states with enhanced reimbursement for comprehensive prenatal care including GDM monitoring and digital health integration. Vendors supplying remote patient monitoring platforms, CGM connectivity solutions, and care coordination software are positioned to capture preferred vendor contracts under TMaH as participating states finalize implementation plans through 2025 and 2026. This model represents a direct government procurement channel worth an estimated USD 370 million in incremental GDM-related services over its initial performance period.

A second major opportunity stems from the 21st Century Cures Act's interoperability mandates, enforced by ONC through the Information Blocking Rule (45 CFR Part 171), which compels health systems to share structured GDM patient data via FHIR APIs. This regulatory environment enables digital therapeutics companies to build GDM population health tools using real-world EHR data at scale—a capability previously restricted by fragmented data access. Companies including Welldoc and Teladoc Health are already positioning GDM-specific platforms to exploit this data access architecture. Additionally, the IRS's updated HSA-eligible expense guidance covering CGM devices without a prescription creates a price-sensitive consumer demand channel among commercially insured pregnant women, broadening market access beyond prescription-dependent distribution models.

Market at a Glance

Leading Market Participants

• Medtronic
• Abbott Laboratories
• Dexcom
• Novo Nordisk
• Roche Diagnostics
• Sanofi
• Eli Lilly and Company
• Becton Dickinson
• Welldoc
• Teladoc Health

Regulatory and Policy Environment

The primary legislative framework governing the U.S. gestational diabetes market is the Affordable Care Act (Public Law 111-148), supplemented by the Consolidated Appropriations Acts of 2021, 2022, and 2023, which extended and expanded telehealth flexibilities originally introduced under the COVID-19 Public Health Emergency. The USPSTF's 2021 reaffirmed recommendation (Grade B) for GDM screening after 24 weeks of gestation in asymptomatic pregnant women is the clinical mandate that triggers ACA coverage obligations. The FDA's CDRH administers device clearance, while CMS administers reimbursement through Medicare and Medicaid. The American Diabetes Association's annually updated Standards of Care in Diabetes serve as the de facto clinical compliance benchmark referenced by payers in coverage determinations, creating a quasi-regulatory influence that companies must actively monitor.

Compared to regional peers, the U.S. regulatory framework is more favorable to device innovation than the EU's MDR 2017/745, which imposes stricter clinical evidence requirements for Class IIb diagnostic devices including CGMs. However, the U.S. lacks the unified national formulary structure present in the UK's NHS, meaning that commercial negotiation across thousands of individual payer contracts creates higher market access complexity. Expected regulatory developments include FDA's anticipated final guidance on digital health technologies in maternal care (projected Q3 2025) and CMS's proposed rule on remote therapeutic monitoring reimbursement expansion (comment period closed January 2025), both of which will directly affect GDM product and service reimbursement pathways before the 2026 forecast window opens.

Long-Term Policy Outlook for U.S. Gestational Diabetes

By 2032, the U.S. gestational diabetes market will be reshaped by three anticipated policy trajectories. Telehealth permanency legislation, expected before the current statutory extensions expire in 2027, will codify remote monitoring reimbursement for high-risk obstetric patients including those with GDM, permanently expanding the addressable market for CGM-integrated digital care platforms. Additionally, the Biden-era White House Blueprint for Addressing the Maternal Health Crisis—which allocated USD 470 million across HHS agencies—will mature into structured Medicaid reimbursement reforms by 2026–2028, with explicit GDM management components embedded in value-based obstetric care payment models across at least 20 states.

The FDA is expected to issue a final rule on AI-enabled clinical decision support tools in obstetrics by 2027, which will create a new regulatory classification pathway for GDM risk prediction algorithms currently operating in a regulatory gray zone. This will force companies like Welldoc, Vida Health, and emerging AI diagnostics entrants to pursue formal FDA authorization, raising compliance costs but also creating durable competitive moats for early authorized products. Concurrently, the growing congressional focus on postpartum care—evidenced by the Momnibus Act provisions included in piecemeal legislation since 2021—signals likely expansion of Medicaid postpartum coverage duration from 12 months to 24 months in additional states, sustaining GDM-related monitoring and therapeutic demand well beyond the delivery episode and materially expanding the lifetime patient value for market participants.